Username:
Password:
Enter your email below to subscribe to our Health & Biotech News Digest.

All News

Dec 16, 2008
MabVax Therapeutics Receives Two Small Business Technology Transfer Program Awards From The National Cancer Institute
San Diego, CA, December 16, 2008 -- MabVax Therapeutics Inc., a privately held immunotherapeutics discovery and development company focused on the development and commercialization of novel immunotherapies for the treatment of cancer, announced the company has received two grant awards from t Read More...
Filed Under: GBP Captial News



Dec 04, 2008
Lentigen and PATH Announce Partnership on Innovative Vaccine for Pandemic Influenza
Seattle, WA and Gaithersburg, MD, December 4, 2008—The biotech company Lentigen Corporation and the nonprofit global health organization PATH announced today a partnership to accelerate research on a pandemic influenza vaccine. PATH will initially invest $3 million over 27 months and wo Read More...
Filed Under: GBP Captial News



Oct 01, 2008
Lentigen Corporation and the United States Army Agree to Contract
GAITHERSBURG, Md., Oct 01, 2008 /PRNewswire via COMTEX/ -- Lentigen Corporation announced today that it has established a contract with the United States Army to extend the programs established in the initial agreement announced in 2006. This contract is for a further phase of Lentigen Corpor Read More...
Filed Under: GBP Captial News



Aug 14, 2008
Flexible Stenting Solutions Announces Successful Completion of First-in-Man Study of Third Generation Peripheral Arterial Stent
Eatontown , NJ - Flexible Stenting Solutions Inc., a leading developer of third generation peripheral arterial stents, announced today that a physician at Auckland City Hospital in New Zealand successfully implanted several of its third generation arterial Read More...
Filed Under: GBP Captial News



Aug 12, 2008
MabVax Therapeutics Closes Two Licensing Agreements With Sloan-Kettering Institute for Cancer Research
San Diego, CA, August 12, 2008 -- MabVax Therapeutics Inc., a privately held immunotherapeutics discovery and development company focused on the development and commercialization of novel immunotherapies for the treatment of cancer, today announced the completion of two separate licensing Read More...
Filed Under: GBP Captial News



Aug 04, 2008
Lentigen, Invitrogen to Provide Lentivirus Products and Services for Gene Over-Expression
CARLSBAD, Calif. & BALTIMORE-- Invitrogen Corporation (NASDAQ:IVGN), a provider of essential life science technologies for research, production and diagnostics, and Lentigen Corporation, a privately-held biotechnology company specializing in the development and manufacture of lentivira Read More...
Filed Under: Company News



Jul 17, 2008
APMA Announces HyperMed's New Technology Predicts Healing Potential of Diabetic Ulcers - May Prevent Devastating Diabetic Limb Amputations
Burlington, MA – July 17, 2008 – Today the American Podiatric Medical Association (APMA) announced that HyperMed's OxyVu™ imaging system may predict healing of diabetic ulcers. OxyVu™ uses proprietary technology pioneered by HyperMed in the first medical application of Read More...
Filed Under: Company News



Jun 15, 2008
Lentigen Corporation Receives Four Research Grants from the National Institute of Health
Baltimore, MD (May 15, 2008) – Lentigen Corporation announced today that it has received four National Institutes of Health (NIH) small business innovation research (SBIR) grants to collaborate with leading scientists. Through these grants, Lentigen will Read More...
Filed Under: Company News



May 19, 2008
HyperMed, Inc. Receives Additional $4 Million from GBP Capital
Burlington, MA – May 19, 2008 – HyperMed, Inc., the leader in hyperspectral medical imaging, today announces it completed $4 million financing from GBP Capital (GBP) this month. Proceeds will support ongoing marketing and sales of OxyVu™, its lead product. Mark Carbeau Read More...
Filed Under: GBP Captial News



Apr 21, 2008
Mark B. Carbeau Appointed Director, Chief Executive Officer and President of HyperMed, Inc, Daniel J. Levangie To Serve as Chairman of the Board of Directors
Burlington, MA – April 21, 2008 – HyperMed, Inc., the developer and manufacturer of hyperspectral diagnostic systems with application in diabetic and vascular disease, today announces the appointment of Mark B. Carbeau as Director, Chief Executive Officer, and President, effective Read More...
Filed Under: Company News



43 results:

1234...5>>


© 2007 GBP Capital. All Rights Reserved. Legal | Privacy Statement | Sitemap